Johnson & Johnson (NYSE: JNJ ) is among them 13 Best Defensive Stocks for 2025.
On March 3, BofA analyst Jason Gerberi increased the company’s price recommendation on Johnson & Johnson (NYSE:JNJ) from $227 to $253. It reiterated a neutral rating on the shares. The company said it has updated its long-term revenue estimates to reflect new expectations for several pipeline assets nearing market. Gerberi specifically mentions Tikvelli and Anleczo. He also noted that Tecvayli’s stronger data could have a knock-on effect on Darzalex by extending the duration of treatment.
A few days later, on March 5, Reuters reported that Johnson & Johnson had launched a website that would allow some patients in the United States to buy some drugs directly. The platform is designed for people who don’t have insurance or pay out-of-pocket for drugs. The website, called J&J Direct, currently lists three drugs. These include the diabetes treatments Invokana and Invokamet, along with the blood thinner Xarelto.
The initiative ties in with a broader commitment the company made earlier this year. In January, Johnson & Johnson agreed to improve direct access to its medicines as part of a deal with US President Donald Trump’s administration. The agreement included plans to lower prices in exchange for exemptions from tariffs. The company also promised to invest 55 billion dollars in the United States over a period of four years.
Johnson & Johnson (NYSE: JNJ ) operates in many areas of healthcare. Through its subsidiaries, the company focuses on research and development, manufacturing, and sales of healthcare products. Its operations are organized into two segments: Innovative Medicines and MedTech.
While we recognize JNJ’s potential as an investment, we believe some AI stocks offer higher potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: The 40 most popular stocks among hedge funds heading into 2026 And the 15 best stocks to buy now for passive income
Disclosure: None. Follow the inside port on Google News.
(translating tags) Johnson & Johnson
